Contact Us
Drug Search Results
More Filters [+]

Ciprofibrate

Alternative Names: ciprofibrate
Latest Update: 2024-02-12
Latest Update Note: PubMed Publication

Product Description

Ciprofibrate is a monocarboxylic acid, a member of cyclopropanes and an organochlorine compound. It has a role as an antilipemic drug. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ciprofibrate)

Mechanisms of Action: PPAR-a Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Colombia | Czech | Dominican Republic | Ecuador | France | Hungary | India | Indonesia | Ireland | Israel | Korea | Luxembourg | Mexico | Morocco | Netherlands | Peru | Philippines | Poland | Portugal | Russia | Serbia | Tunisia | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hospital Universitario Pedro Ernesto
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ciprofibrate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Insulin Resistance

Phase 3: Prediabetic State|Insulin Resistance

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
FIT

P3

Completed

Insulin Resistance|Prediabetic State

2020-11-06

Ciprofibrate and pre-diabetes

P4

Completed

Insulin Resistance

2020-11-06

Recent News Events

Date

Type

Title

02/12/2024

PubMed

 Electrochemical N-Aroylation of Sulfoximines by Using Benzoyl Hydrazines with H2 Generation.

01/10/2024

PubMed

 Identification and validation of platelet-related diagnostic markers and potential drug screening in ischemic stroke by integrating comprehensive bioinformatics analysis and machine learning.

10/01/2023

PubMed

 The tissue-specific metabolic effects of the PPARalpha agonist ciprofibrate in insulin-resistant male individuals: a double-blind, randomized, placebo-controlled crossover study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions